P-79 C-PRECISE-01 study: A phase Ib/II trial of MEN1611, a PI3K inhibitor, and cetuximab in patients with PIK3CA mutated metastatic colorectal cancer failing irinotecan, oxaliplatin, 5-FU and anti-EGFR containing regimensJosep Tabernero, Angela Capriati, François Ghiringhelli et al.|Annals of Oncology|2020Cited by 5
MEN1112/OBT357, an Anti Bst1/CD157 Humanized Antibody Inducing Acute Myelogenous Leukemia (AML) Blast Depletion in an Autologous Ex Vivo Assay: A Potential New Targeted Therapy for AMLAdriano Venditti, Giuseppe Sconocchia, Andrea Coppola et al.|Blood|2015Cited by 4